<?xml version="1.0" encoding="UTF-8"?>
<p id="p0260">Previous studies in MERS suggested that convalescent plasma may be effective.
 <xref rid="bib57" ref-type="bibr">
  <sup>57</sup>
 </xref> Mair-Jenkins etÂ al. further suggested that convalescent plasma may reduce mortality in patients with SARI of viral etiology.
 <xref rid="bib58" ref-type="bibr">
  <sup>58</sup>
 </xref> The NHC (trial version 2) includes convalescent plasma as a potential treatment in severe cases, critical cases, and cases of rapidly worsening clinical status.
 <xref rid="bib59" ref-type="bibr">
  <sup>59</sup>
 </xref> Donors and recipients should be carefully selected, and serum-specific IgG antibodies for SARS-CoV-2 should be tested to guarantee the quality of convalescent plasma. Critical patients who received convalescent plasma showed significant improvement in clinical symptoms and laboratory findings.
 <xref rid="bib60" ref-type="bibr">
  <sup>60</sup>
 </xref> Multiple clinical trials have been registered in the Chinese Clinical Trial Registry to study the safety and efficacy of convalescent plasma treatment in COVID-19 patients.
 <xref rid="bib61" ref-type="bibr">
  <sup>61</sup>
 </xref>
</p>
